Aphria RX (Tilray Deutschland)

What we could verify

Aphria RX GmbH is a documented subsidiary of Tilray Brands, Inc., headquartered in Neumünster, Schleswig-Holstein, Germany. Strong evidence In April 2019, it was one of three companies awarded multi-year cultivation contracts under the German Federal Institute for Drugs and Medical Devices (BfArM) tender to grow medical cannabis domestically. Strong evidence^[1][2] Aphria RX received five of the 13 allocated cultivation lots—the largest single award at the time. Strong evidence^[1]

Originally a subsidiary of Canadian licensed producer Aphria Inc., Aphria RX became part of Tilray Brands in May 2021 when Aphria Inc. and Tilray Inc. completed a reverse merger. Strong evidence^[3] Today the company operates under the Tilray Deutschland corporate identity in the German market. Strong evidence^[4]

Under the BfArM contract, harvested flower is sold to the Cannabisagentur (the cannabis agency within BfArM), which distributes to wholesalers and pharmacies at a regulated price. Strong evidence Following Germany's Cannabis Act (CanG), which took effect 1 April 2024, medical cannabis was reclassified off the narcotics list, expanding prescribing pathways. Strong evidence^[5]

Why the name alone is not evidence

Many cannabis brands and strain names circulate online without reliable documentation. A product label or website bearing the name 'Aphria RX' or 'Tilray Deutschland' does not confirm: the cultivator's identity, cannabinoid content, terpene profile, batch testing, or legal origin. No data

Strain names are often applied loosely across the industry and are not registered or enforced by any regulatory body in most jurisdictions. Weak / limited^[6] Similarly, THC and CBD percentages advertised on third-party sites often lack corresponding lab reports, and marketing claims about effects or quality are not independently verified by Weedpedia or BfArM. No data

What to verify if you see it for sale

If you encounter a product claiming to be from Aphria RX or Tilray Deutschland:

Certificate of analysis (CoA): Obtain a current, batch-specific lab report showing THC, CBD, and residual-solvent testing. Verify the lab name, testing date, and batch code match the product. No data

Source channel: Legitimate medical cannabis from this supplier flows through German pharmacies on prescription. Any direct-to-consumer website shipping across borders is operating outside the regulated framework. Strong evidence

Parent company: Confirm current ownership via Tilray Brands' most recent SEC 10-K filing or annual report. Strong evidence^[4]

BfArM status: The original 2019 award was for a multi-year contract; current cultivation volumes and cultivar lists are not necessarily static. Check the Cannabisagentur website for current product availability. Strong evidence

Breeder and lineage claims: If a seller claims a specific parentage, growing history, or award, ask for documentation. Marketing accolades from trade shows are not verified by BfArM and do not indicate product quality. No data

Corporate and regulatory context

Tilray Brands' parent companies have faced shareholder litigation and scrutiny from short-seller reports. In 2018, Quintessential Capital and Hindenburg Research published allegations regarding Aphria Inc.'s Latin American asset acquisitions, triggering regulatory review and class-action litigation. Strong evidence^[6] Tilray Brands has also faced shareholder lawsuits concerning merger disclosures and forecasts. Strong evidence^[4] None of these matters establish wrongdoing by the Neumünster cultivation entity itself; they are part of the public record on the parent group.

We are not aware of any public regulatory finding against Aphria RX relating to product safety or breach of its BfArM contract as of the last-checked date. Absence of public complaint is not a guarantee of safety. No data

Availability and legal-market notes

Aphria RX / Tilray Deutschland product is available in Germany on prescription through licensed pharmacies only. It is not sold direct-to-consumer and is not legally exported to private buyers in other countries. Strong evidence^[5] Any website offering to ship this product across borders to private consumers is circumventing German and international narcotics law.

Following the Cannabis Act (CanG, April 2024), medical cannabis in Germany is no longer classified as a narcotic, which simplified prescribing pathways. However, the licensed-producer supply model that Aphria RX operates within remains unchanged. Strong evidence^[5]

Flag an error or provide documentation

If you have a current breeder record, lab certificate, or official company document regarding Aphria RX that contradicts or clarifies this profile, please contact Weedpedia. We prioritize sourced, verifiable information over hearsay or marketing claims. No data

Sources

How this page was made

Related

• Tilray Brands — Publicly traded holding company operating cannabis and beverage brands across multiple jur...
• Tilray Portugal — Medical cannabis producer and subsidiary of Tilray Brands operating in Portugal.